Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹3,509 Cr
Revenue (TTM)
₹7 Cr
Net Profit (TTM)
₹-275 Cr
ROE
-84.9 %
ROCE
-84.5 %
P/E Ratio
--
P/B Ratio
5.3
Industry P/E
33.39
EV/EBITDA
-13
Div. Yield
0 %
Debt to Equity
0
Book Value
₹25.2
EPS
₹-12.3
Face value
1
Shares outstanding
263,720,583
CFO
₹-549.70 Cr
EBITDA
₹-316.10 Cr
Net Profit
₹-413.63 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Suven Life
| -19.9 | -12.7 | -20.3 | 12.5 | 38.3 | 14.1 | 4.4 |
|
BSE Healthcare
| -4.0 | -3.8 | -4.0 | 3.0 | 24.6 | 15.5 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Suven Life
| 30.0 | 55.7 | 18.0 | -16.6 | -2.4 | -70.5 | 32.3 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Suven Life
|
133.1 | 3,508.8 | 7.1 | -274.7 | -4,008.3 | -140.4 | -- | 5.3 |
| 337.6 | 3,082.6 | 2,521.8 | 202.5 | 9.6 | 14.3 | 15.2 | 2.0 | |
| 928.1 | 11,377.1 | 2,512.3 | 543.7 | 28.3 | 19.3 | 20.9 | 3.6 | |
| 365.5 | 6,335.0 | 1,053.1 | 293.6 | 32.3 | 24.6 | 21.6 | 4.9 | |
| 1,101.0 | 11,521.9 | 1,158.7 | 309.6 | 31.9 | 17.3 | 36.9 | 6.1 | |
| 1,470.8 | 27,865.9 | 8,850.1 | 894.8 | 15.2 | 19.8 | 32 | 5.6 | |
| 275.7 | 2,996.5 | 159.3 | 47.8 | 39.0 | 18.6 | 62.7 | 10.8 | |
| 12,101.0 | 15,516.2 | 1,575.1 | 179.1 | 14.9 | 11.4 | 86.6 | 9.3 | |
| 1,822.9 | 3,011.8 | 673.7 | 202.6 | 17.6 | 19.4 | 14.9 | 5.2 | |
| 738.9 | 3,404.5 | 588.5 | 102.9 | 22.1 | 12.7 | 33.5 | 4.0 |
No Review & Analysis are available.
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and... internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for treating sleep and cognitive disorders; and Ropanicant (SUVN-911), an Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders. The company is also developing Usmarapride (SUVN-D4010), a bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for treating cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for treating gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is based in Hyderabad, India. Suven Life Sciences Limited operates as a subsidiary of Jasti Property and Equity Holdings Private Limited. Read more
Incorporated
1989
Chairman
Venkateswarlu Jasti
Managing Director
Venkateswarlu Jasti
Headquarters
Hyderabad, Telangana
Website
Looking for more details about Suven Life Sciences Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Suven Life Sciences Ltd is ₹133.10 (NSE) and ₹133.05 (BSE) as of 19-Mar-2026 IST. Suven Life Sciences Ltd has given a return of 38.32% in the last 3 years.
Since, TTM earnings of Suven Life Sciences Ltd is negative, P/E ratio is not available.
The P/B ratio of Suven Life Sciences Ltd is 5.28 times as on 19-Mar-2026, a 144 premium to its peers’ median range of 2.16 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
22.75
|
|
2024
|
0.00
|
8.05
|
|
2023
|
0.00
|
2.82
|
|
2022
|
0.00
|
14.02
|
|
2021
|
0.00
|
12.61
|
The 52-week high and low of Suven Life Sciences Ltd are Rs 299.99 and Rs 113.00 as of 19-Mar-2026.
Suven Life Sciences Ltd has a market capitalisation of ₹ 3,509 Cr as on 19-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Suven Life Sciences Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-5.00
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.